News & Updates
Filter by Specialty:
Idecabtagene vicleucel boosts PFS and responses vs standard regimens in triple class–exposed R/R MM
Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, improves progression-free survival (PFS) and responses vs standard regimens in patients with triple class–exposed relapsed and refractory multiple myeloma (R/R MM), the phase III KarMMa-3 trial has shown.
Idecabtagene vicleucel boosts PFS and responses vs standard regimens in triple class–exposed R/R MM
17 Apr 2023
Endoscopic submucosal dissection safer, more cost-effective than transanal endoscopic microsurgery
In patients with early rectal cancer (ERC), endoscopic submucosal dissection (ESD) appears safer and is associated with shorter hospital stay than transanal endoscopic microsurgery (TEM), results of a recent study have shown.
Endoscopic submucosal dissection safer, more cost-effective than transanal endoscopic microsurgery
15 Apr 2023
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
The angiotensin receptor neprilysin inhibitor sacubitril/valsartan, used for heart failure, appears to have potent effects on 24‐hour blood pressure (BP) in Japanese patients with mild‐to‐moderate hypertension and in the subgroup of those with nondipping BP pattern, as shown in a study.
HF drug provides 24-hour BP-lowering effect in Asians with hypertension
15 Apr 2023
Hysteroscopy not better than vacuum aspiration for managing incomplete miscarriage
The use of hysteroscopy for surgical management of incomplete spontaneous abortion in individuals who intend to conceive again neither leads to more subsequent births nor shows a better safety profile compared with vacuum aspiration, according to the results of the HY-PER trial.
Hysteroscopy not better than vacuum aspiration for managing incomplete miscarriage
14 Apr 2023
Excessive air swallowing linked to dyspepsia, poor response to PPI therapy
Swallowing more air appears to induce both dyspepsia and refractoriness to typical symptoms of gastroesophageal reflux disease (GERD) to proton pump inhibitor (PPI) therapy, suggests a study.
